CBL Biopharma

Pharmaceutical ManufacturingUnited States11-50 Employees

Over the past 20 years, CBL has developed a reputation as a premier supplier and manufacturer in the peptide industry. CBL is best known for having developed and commercialised trityl resins, such as 2-chlorotrityl chloride resin. This resin has grown to be one of the most widely used for solid phase peptide synthesis. CBL’s expertise includes manufacture of peptide starting materials, GMP production of peptide intermediates, and API and peptide technology.

CBL offers a wide range of high-quality starting materials and intermediates for solid phase peptide synthesis. Competitively priced material is produced at large scale. GMP production of peptide clinical and commercial material is offered at all stages of the drug development process.  

CBL operates out of 10,000 square state-of-the-art laboratory and production space built for peptide synthesis located in Patras, Greece. In 2007, the company opened a new building that houses GMP production facilities including more than 20 clean rooms.  To better service the US market, CBL operates a warehouse and sales office in Boulder, Colorado.

On-going research programmes to develop new methods and materials for peptides provide CBL with a wealth of publications and intellectual property. The company has discovered a number of solid phase resins and uniquely protected Fmoc amino acids. Additionally, CBL holds IP in complex peptide manufacturing strategies such as for the insulin-like peptides and other peptides in the 30- to 150-amino acid range.

CBL is recognised for high quality standards and customer service. The company was the 2001 and 2002 recipient of the ‘Roche Supplier of the Year’ award.

Sign up for free to view info

Email Format Employee directory